Here comes a big update on KRAS 

If you’re KRAS curious, you’ll want to be near your computer or smartphone today at 4:15 pm ET. That’s when Mirati Therapeutics is presenting preliminary results from a clinical trial of MRTX849, a pill designed to block the “undruggable” cancer protein called KRAS. 

Mirati has only treated a handful of lung and colon cancer patients with MRTX849, but these initial data will be the first opportunity to size up the drug’s efficacy and safety. For investors, it will also invigorate a debate that has simmered for months: Who has the superior KRAS-blocking drug — Mirati or Amgen?

The stakes? Oh, just a few billion dollars in potential revenue. 

STAT’s Adam Feuerstein is attending the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, where the MRTX849 data are being presented. He’ll have all the details, plus instant reaction.